益丰药房(603939) - 2017 Q1 - 季度财报

Financial Performance - Operating revenue for the first quarter was ¥1,078,254,442.24, representing a year-on-year growth of 29.36%[6] - Net profit attributable to shareholders was ¥68,762,614.31, up 32.84% from the same period last year[6] - Basic earnings per share rose to ¥0.191, reflecting a growth of 17.18% year-on-year[6] - The company reported a net profit increase, with retained earnings rising to ¥182,504,742.70 from ¥150,690,441.19, an increase of 21.1%[27] - Net profit for Q1 2017 reached CNY 31,814,301.51, representing a growth of 35.4% from CNY 23,522,258.47 in Q1 2016[34] - Operating profit for Q1 2017 was CNY 42,166,456.98, up 36.5% from CNY 30,997,493.29 in the previous year[33] - The total profit for Q1 2017 was CNY 42,484,115.69, an increase of 35.6% from CNY 31,327,307.46 in the same period last year[34] Cash Flow - Net cash flow from operating activities increased by 37.67% to ¥78,352,079.85 compared to the previous year[6] - Cash flow from operating activities for Q1 2017 was CNY 1,217,418,468.94, an increase of 26.4% compared to CNY 963,828,364.83 in the previous year[36] - Net cash flow from operating activities was CNY 78,352,079.85, up from CNY 56,914,526.42, indicating a year-over-year increase of about 37.5%[37] - Total cash outflow from operating activities was CNY 1,140,746,027.65, compared to CNY 908,866,266.96, reflecting an increase of approximately 25.4%[37] - The company reported a net cash flow from operating activities of CNY 19,535,821.36, down from CNY 49,602,115.67, indicating a decline of about 60.7%[39] Assets and Liabilities - Total assets at the end of the reporting period reached ¥4,240,702,774.06, an increase of 0.46% compared to the end of the previous year[6] - Non-current assets totaled ¥1,097,997,563.17, slightly up from ¥1,095,528,275.83 at the beginning of the year[22] - Total liabilities amounted to ¥1,195,169,139.40, down from ¥1,245,897,751.02, indicating a decrease of about 4.1%[23] - Current liabilities decreased to ¥1,149,424,046.64 from ¥1,200,021,860.36, a reduction of approximately 4.2%[22] - Owner's equity rose to ¥3,045,533,634.66 from ¥2,975,348,493.88, marking an increase of 2.4%[23] Shareholder Information - The total number of shareholders at the end of the reporting period was 14,815[11] - The largest shareholder, Hunan Yifeng Pharmaceutical Investment Management Co., Ltd., held 29.27% of the shares[11] Store Expansion and Operations - As of March 31, 2017, the company had a total of 1,595 stores, with a net increase of 60 stores during the first quarter, including 59 new openings and 3 acquisitions[14] - The company plans to continue expanding its store network and enhancing operational efficiency to drive future growth[14] Financial Management - The company's financial expenses decreased significantly by 440.16%, resulting in a net financial income of RMB -9,411,837.45, mainly due to increased interest income from financial management[14] - The company completed four acquisition projects during the reporting period, with total transaction amounts reaching RMB 2,123,000 for one project and RMB 582,000 for another[16][17] Inventory and Accounts Payable - The total amount of accounts payable increased by 31.55% to RMB 322,945,639.23, attributed to expanded procurement scale[14] - The company reported a decrease in other payables by 30.17% to RMB 48,670,029.89, primarily due to payments related to acquisition progress[14] - The company’s inventory decreased to RMB 699,634,307.80 from RMB 730,060,057.55, indicating improved inventory management[21]